QLT Inc.  

(Public, TSE:QLT)   Watch this stock  
Find more results for QLT
+0.08 (1.77%)
May 22 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 4.59 - 4.60
52 week 3.91 - 7.35
Open 4.60
Vol. 4,580.00
Mkt cap 235.60M
P/E     -
Div/yield     -
EPS -0.08
Shares 51.26M
Beta -0.53
Inst. own     -
Aug 4, 2015
Q2 2015 QLT Inc Earnings Release (Estimated) Add to calendar
Apr 30, 2015
Q1 2015 QLT Inc Earnings Release
Feb 26, 2015
Q4 2014 QLT Inc Earnings Release

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -14.98% -2.47%
Return on average equity -15.37% -2.55%
Employees 31 -
CDP Score - -


887 Great Northern Way Suite 250
+1-604-7077000 (Phone)
+1-604-7077001 (Fax)

Website links


QLT Inc. is a Canada-based biotechnology Company. The Company is engaged in the development and commercialization of ocular products. The Company is focused on developing its synthetic retinoid program for the treatment of certain inherited retinal diseases. The Company is engaged in providing transition services to Valeant concerning most of the aspects of the Visudyne and Qcellus laser business. The Company is conducting Phase Ib clinical proof-of-concept studies of QLT091001, a synthetic retinoid replacement therapy for 11-cis-retinal, a key biochemical component of the visual retinoid cycle, in patients with Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP). The Company’s product Visudyne and Eligard are sold to Valeant Pharmaceuticals International, Inc and QLT USA, Inc. respectively.

Officers and directors

Jason M. Aryeh Independent Chairman of the Board
Age: 46
Geoffrey F. Cox Ph.D. Interim Chief Executive Officer, Director
Age: 70
Glen Ibbott Chief Financial Officer
Age: 52
John W. Kozarich Ph.D. Independent Director
Age: 65
Jeffrey A. Meckler Independent Director
Age: 48
Stephen L. Sabba M.D. Independent Director
Age: 55
John C. Thomas Jr. Independent Director
Age: 60